ТОО "ШИК ЛАВ"
This is a company preview
Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.
Risks
0/18Комитет государственных доходов · Государственные закупки РК · АО ФНБ «Самрук-Казына» · АОО «НИШ»This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.
Procurement signals
Court cases
Arrests & encumbrances
Enforcement proceedings
Certificates
Licenses and permits
Summary
Министерство юстиции РКActivities
86909 Прочая деятельность в области здравоохранения, не включенная в другие группировки
Прочая деятельность в области здравоохранения, не включенная в другие группировки
Contacts
Change history
Financial statements
PremiumPublic contracts
What it sells and where
Samruk-Kazyna procurement
Tender bids
Procurement as a customer
Assets
Bank accounts
Leadership
1- ИА
Ибрашева Алмагуль Амангалиевна
Director
Founders
Accreditations
Employees
Affiliated companies
PremiumDirector's involvement in other legal entities
Branches
Company networks
PremiumSimilar companies
Media mentions
Company summary
ТОО "ШИК ЛАВ" (BIN 180740021121) is an active legal entity, registered in 2018, located in Almaty, 8 years on the market. Main activity: healthcare. Small enterprise, headcount: up to 5 employees. Automated screening of open registries found no risk indicators for «ШИК ЛАВ». Latest registry change: change of main activity, May 1, 2024. Founders: 2. Director on record: Ибрашева Алмагуль Амангалиевна. Registry data current as of June 11, 2026.
Data sources and disclaimer
Sources: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is collected automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the fact. This is reference information and does not replace an official extract. Methodology: SafeDeal editorial policy.